What a $2 Million Per Dose Gene Therapy Reveals About Drug Pricing
—
Taxpayers and charities helped develop Zolgensma. Then it debuted at a record price, ushering in a new class of wildly expensive drugs. Its story upends the widely held conception that high prices reflect huge industry investments in innovation.
#News #Health #Healthcare #Medicine #Genetics #Biotech #Science
@ProPublica Thanks for this great article. Keep up the good work!
As an aside, the Généthon (a french non-profit dedicated to fighting rare diseases) contributed to the research that led to Zolgensma, and commented this pricing situation: https://www.afm-telethon.fr/fr/la-therapie-genique-zolgensma-precision-sur-son-prix-et-role-joue-par-genethon.
Roughly translated: "Zolgensma's price results from the current drugs price-fixing system as well as the unability for [France] to transform research in drugs". They notably insist that european countries pay less for therapies than ...
